# EMERALD-1 (NCT03778957)

> A Global Study to Evaluate Transarterial Chemoembolization (TACE) in Combination With Durvalumab and Bevacizumab Therapy in Patients With Locoregional Hepatocellular Carcinoma

No report yet. It can be ordered.

## Registry

- Registry record: https://clinicaltrials.gov/study/NCT03778957
- Phase: PHASE3
- Status: ACTIVE_NOT_RECRUITING
- Sponsor: AstraZeneca
- Conditions: Hepatocellular Carcinoma
- Interventions: Durvalumab; Bevacizumab; Placebo; Transarterial Chemoembolization (TACE)
- Enrollment: 724
- Primary outcome: Progression Free Survival (PFS) for Arm B vs Arm C

## Preliminary discovery

Commentary in our index that names this trial so far. Final coverage is set when the report is built.

- X threads: 72
- YouTube: 53
- Podcasts: 34
- Bluesky threads: 3
- X videos: 1

## Order

Deep, $1,950, price fixed at order: https://www.erudio.com/contact?report=emerald-1-nct03778957

## Free preview

POST https://www.erudio.com/api/trial-requests with {"nct_id": "NCT03778957", "email": "<work email>"}; the inbox owner confirms by the emailed link.